Real world evidence market expansion is largely fueled by the expansion of clinical trials and the transition from volume- to value-based care. RWE and RWD may be used to improve protocol design, which will lead to less expensive protocol revisions. They can also be used to create synthetic control arms, which will speed up trial execution and lower expenses overall.